摘要
肺癌已成为21世纪威胁人类健康最主要原因之一,全球每年因非小细胞肺癌(NSCLC)死亡的人数超过100万人。传统的抗肿瘤药物极大改善了NSCLC患者的预后。由于缺乏选择性和很强的细胞毒性,多中心研究表明化疗方案疗效已经达到治疗平台,应致力于研发作用机制不同于化疗的药物。肿瘤靶向治疗通过针对特异性的靶点来杀死和抑制肿瘤细胞,避免了对正常细胞的伤害,已成为当前肿瘤研究的热点,并已在临床肿瘤治疗中取得了一定疗效。随着肿瘤分子生物学与细胞生物学的发展,人们对肺癌癌变、侵袭转移的分子机理以及生物信号传导通路的认识加深,新的靶向治疗药物不断出现。本文就近年靶向治疗技术的进展及分子靶向药物在NSCLC中的应用作一综述。
Lung cancer has become one of the most important reasons threatened to human health in 21 st century. The number of people died of non-small cell lung cancer （NSCLC） has exceeded one million. The traditional antitttmor drug has obviously improved the quality of life of NSCLC patients. But multi-center study suggested the efficacy of traditional chemo-program has already reached its platform due to its lack of selectivity and its strong toxic effect on cells. Targeted therapy kills or inhibits tumor cells by aiming at specific target, and simultaneously avoids the hurt to normal cells, so it became the hot spot in the research of tumor. With the development of oncomolecularbiology and cytobiology, A knowledge of canceration of lung cancer, molecular mechanism of the metastases and the conduction path of biologic signal was deepen, and new molecules drugs for targeted therapy was invented continually. In this paper, the progress of targeted therapy and the application of molecular targeted drugs to the therapy of NSCLC were reviewed.
出处
《现代生物医学进展》
CAS
2008年第3期564-566,570,共4页
Progress in Modern Biomedicine
基金
陕西省攻关课题2005K09-gl(1)
关键词
耙向治疗
分子靶向药物
非小细胞肺癌
Targeted therapy
Molecular targeted drugs
Non-small cell cancer （NSCLC）
